8-K: Boston Scientific Director Sununu to Depart Board

John E. Sununu will not seek re-election to Boston Scientific's Board of Directors at the 2026 Annual Meeting, concluding 17 years of service.

Summary

• John E. Sununu informed Boston Scientific Corporation on October 22, 2025, that he will not stand for re-election at the Company's 2026 Annual Meeting of Stockholders.
• Mr. Sununu has served as a member of the Board of Directors since April 2009.
• He currently serves as a member of the Audit Committee and as the chair of the Nominating and Governance Committee.
• Mr. Sununu will continue to serve as a director and in his committee roles until the 2026 Annual Meeting.
• His decision not to stand for re-election is not the result of any disagreement with the Company.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as a long-serving director is departing without any reported disagreement, suggesting a planned and amicable transition. The company's statement about evaluating board composition is standard practice.

Positives

• The departure of John E. Sununu is explicitly stated not to be the result of any disagreement with the Company, indicating a smooth and amicable transition.

Risks

• The Board and Nominating and Governance Committee will need to effectively evaluate and potentially identify suitable candidates to maintain optimal board composition following Mr. Sununu's departure.

Future Outlook

The Board and Nominating and Governance Committee will continue to evaluate whether adding directors to the Board following Mr. Sununu's departure is in the best interest of the Company.

Management Comments

• Mr. Sununu's decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the Company.

Industry Context

This announcement is an internal corporate governance matter for Boston Scientific and does not directly reflect broader industry trends or competitive shifts within the medical device sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The composition of the Board of Directors will change, potentially impacting governance oversight and strategic direction. The company's statement of no disagreement should reassure shareholders regarding the transition.

Next Steps

• John E. Sununu will continue to serve as a director and in his committee roles until the 2026 Annual Meeting.
• The Board and Nominating and Governance Committee will evaluate whether adding directors to the Board is in the best interest of the Company following Mr. Sununu's departure.

Key Dates

Recommendation

This filing reports a routine corporate governance event—a long-serving director not seeking re-election—without any stated disagreement or immediate operational impact. Such an event is generally not considered material enough to warrant a change in investment recommendation for a company of Boston Scientific's size and stability. Investors should monitor the process for selecting a replacement but the current news itself is neutral.

Keywords

Boston Scientific, BSX, Board of Directors, Corporate Governance, Director Departure, Audit Committee, Nominating and Governance Committee, SEC Filing, Healthcare, Medical Devices